TY - JOUR
T1 - Factorsinfluencing immunogenicityand safety of two Haemophilus influenzae type b polysaccharide vaccines in children 18 and 24 months of age
AU - Greenberg, David P.
AU - Ward, Joel I.
AU - Burkart, Kelly
AU - Christenson, Peter D.
AU - Guravitz, Lisa
AU - Marcy, S. Michael
PY - 1987/1/1
Y1 - 1987/1/1
N2 - The purpose of this study was to evaluate differences in the safety and immunogenicity of Haemophilus influenzae type b (Hib) capsular polysaccharide vaccine produced by two manufacturers (Connaught and Praxis) in children 18 and 24 months of age. Eighty-five children were evaluated in a prospective, doubleblind, randomized fashion. Postvaccination antibody concentrations (measured by radioimmunoassay) and response rates were not significantly differ-ent between the two manufacturers' vaccines but immunogenicity was significantly less in 18-month-old children (antibody concentration, 0.149 jug/ml) compared with 24-month-old children (0.838 iig/ml) (P = 0.001). No significant differences were noted in the safety of the two vaccines. This study suggests that previously observed differences of immunogenicity data between various type b capsular polysaccharide vaccines are due to differences in antibody assays, not in vaccines. Eighteen-month-old children appear to have a relatively poor immune response to type b capsular polysaccharide. Therefore to optimize the benefits of immunization, we suggest children receive this vaccine at 24 months of age.
AB - The purpose of this study was to evaluate differences in the safety and immunogenicity of Haemophilus influenzae type b (Hib) capsular polysaccharide vaccine produced by two manufacturers (Connaught and Praxis) in children 18 and 24 months of age. Eighty-five children were evaluated in a prospective, doubleblind, randomized fashion. Postvaccination antibody concentrations (measured by radioimmunoassay) and response rates were not significantly differ-ent between the two manufacturers' vaccines but immunogenicity was significantly less in 18-month-old children (antibody concentration, 0.149 jug/ml) compared with 24-month-old children (0.838 iig/ml) (P = 0.001). No significant differences were noted in the safety of the two vaccines. This study suggests that previously observed differences of immunogenicity data between various type b capsular polysaccharide vaccines are due to differences in antibody assays, not in vaccines. Eighteen-month-old children appear to have a relatively poor immune response to type b capsular polysaccharide. Therefore to optimize the benefits of immunization, we suggest children receive this vaccine at 24 months of age.
UR - http://www.scopus.com/inward/record.url?scp=0023262043&partnerID=8YFLogxK
U2 - 10.1097/00006454-198707000-00008
DO - 10.1097/00006454-198707000-00008
M3 - Article
AN - SCOPUS:0023262043
VL - 6
SP - 660
EP - 665
JO - Pediatric Infectious Disease Journal
JF - Pediatric Infectious Disease Journal
SN - 0891-3668
IS - 7
ER -
